Skip to main content
. 2020 Apr 28;8(2):203. doi: 10.3390/vaccines8020203

Figure 1.

Figure 1

Figure 1

Figure 1

(a) OS in patients with and without liver metastases; (b) OS in patients with and without brain metastases; (c) OS in patients with and without bone metastases; (d) OS in patients treated with immunotherapy upfront or in subsequent lines; (e) OS in different histologies; (f) OS in patients affected by squamous and non-squamous NSCLC or other cancers.